State of pneumococcal vaccine immunity

References

• Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–6. doi:10.1038/s41579-018-0001-8.
   PubMed Web of Science ®Google Scholar
• Kanswal S, Katsenelson N, Selvapandiyan A, Bram RJ, Akkoyunlu M. Deficient TACI expression on B lymphocytes of newborn mice leads to defective ig secretion in response to BAFF or APRIL. J Immunol. 2008;181(2):976–90. doi:10.4049/jimmunol.181.2.976.
   PubMed Web of Science ®Google Scholar
• Kocabas C, Katsenelson N, Kanswal S, Kennedy MN, Cui X, Blake MS, Segal DM, Akkoyunlu M. Neisseria meningitidis type C capsular polysaccharide inhibits lipooligosaccharide-induced cell activation by binding to CD14. Cell Microbiol. 2007;9(5):1297–310. doi:10.1111/j.1462-5822.2006.00872.x.
   PubMed Web of Science ®Google Scholar
• Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. mBio. 2020;11(3). doi:10.1128/mBio.00937-20.
   Web of Science ®Google Scholar
• Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26(43):5521–6. doi:10.1016/j.vaccine.2008.07.071.
   PubMed Web of Science ®Google Scholar
• Aceil J, Avci FY. Pneumococcal surface proteins as virulence factors, immunogens, and conserved vaccine targets. Front Cell Infect Microbiol. 2022;12:832254. doi:10.3389/fcimb.2022.832254.
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans. Clin Microbiol Infect. 2012;18(Suppl 5):15–24. doi:10.1111/j.1469-0691.2012.03943.x.
   PubMed Web of Science ®Google Scholar
• Guttormsen HK, Wetzler LM, Finberg RW, Kasper DL. Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model. Infect Immun. 1998;66(5):2026–32. doi:10.1128/IAI.66.5.2026-2032.1998.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597–606. doi:10.1016/S1473-3099(07)70210-4.
   PubMed Web of Science ®Google Scholar
• Cripps AW, Folaranmi T, Johnson KD, Musey L, Niederman MS, Buchwald UK. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. Expert Rev Vaccines. 2021;20(3):257–67. doi:10.1080/14760584.2021.1889374.
   PubMed Web of Science ®Google Scholar
• Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol. 2002;169(11):6149–53. doi:10.4049/jimmunol.169.11.6149.
   PubMed Web of Science ®Google Scholar
• Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13(1):655–92. doi:10.1146/annurev.iy.13.040195.003255.
   PubMedGoogle Scholar
• Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491–502. doi:10.1038/nri2572.
   PubMed Web of Science ®Google Scholar
• Sakai J, Akkoyunlu M. The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev. 2017;30(4):991–1014. doi:10.1128/CMR.00046-17.
   PubMed Web of Science ®Google Scholar
• von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001;14(5):573–82. doi:10.1016/S1074-7613(01)00130-3.
   PubMed Web of Science ®Google Scholar
• Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001;2(7):638–43. doi:10.1038/89790.
   PubMed Web of Science ®Google Scholar
• Chinen J, Martinez-Gallo M, Gu W, Cols M, Cerutti A, Radigan L, Zhang L, Potocki L, Withers M, Lupski JR, et al. Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome. J Allergy Clin Immunol. 2011;127(6):1579–86. doi:10.1016/j.jaci.2011.02.046.
   PubMed Web of Science ®Google Scholar
• Akkoyunlu M. TACI expression is low both in human and mouse newborns. Scand J Immunol. 2012;75(3):368–. doi:10.1111/j.1365-3083.2011.02651.x.
   PubMed Web of Science ®Google Scholar
• Schatorje EJ, Gemen EF, Driessen GJ, Leuvenink J, van Hout RW, van der Burg M, de Vries E. Age-matched reference values for B-lymphocyte subpopulations and CVID classifications in children. Scand J Immunol. 2011;74(5):502–10. doi:10.1111/j.1365-3083.2011.02609.x.
   PubMed Web of Science ®Google Scholar
• Sen G, Khan AQ, Chen Q, Snapper CM. In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J Immunol. 2005;175(5):3084–91. doi:10.4049/jimmunol.175.5.3084.
   PubMed Web of Science ®Google Scholar
• Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins: ii. Immunological specificity of synthetic sugar-protein antigens. J Exp Med. 1929;50(4):533–50. doi:10.1084/jem.50.4.533.
   PubMedGoogle Scholar
• van den Biggelaar AH, Pomat WS. Immunization of newborns with bacterial conjugate vaccines. Vaccine. 2013;31(21):2525–30. doi:10.1016/j.vaccine.2012.06.019.
   PubMed Web of Science ®Google Scholar
• Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ, Moore RN. Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide. Infect Immun. 1999;67(2):789–93. doi:10.1128/IAI.67.2.789-793.1999.
   PubMed Web of Science ®Google Scholar
• Eskola J, Kayhty H, Peltola H, Karanko V, Makela PH, Samuelson J, Gordon L. Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine. Lancet. 1985;1(8439):1184–6. doi:10.1016/S0140-6736(85)92863-6.
   PubMed Web of Science ®Google Scholar
• Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD, Stephens DS, Farley MM, Harvey C, et al. Decline of childhood Haemophilus influenzae type b (hib) disease in the hib vaccine era. JAMA. 1993;269(2):221–6. doi:10.1001/jama.1993.03500020055031.
   PubMed Web of Science ®Google Scholar
• Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25(3):409–19. doi:10.1128/CMR.00018-12.
   PubMed Web of Science ®Google Scholar
• Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147(6):1100. doi:10.1093/infdis/147.6.1100.
   PubMed Web of Science ®Google Scholar
• Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21(23):3265–72. doi:10.1016/S0264-410X(03)00230-5.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–20. doi:10.1038/nri2494.
   PubMed Web of Science ®Google Scholar
• Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med. 2011;17(12):1602–9. doi:10.1038/nm.2535.
   PubMed Web of Science ®Google Scholar
• Gilsdorf JR. Hib vaccines: their impact on Haemophilus influenzae type b disease. J Infect Dis. 2021;224(Suppl Supplement_4):321–30. doi:10.1093/infdis/jiaa537.
   Google Scholar
• Duke JA, Avci FY. Emerging vaccine strategies against the incessant pneumococcal disease. NPJ Vaccines. 2023;8(1):122. doi:10.1038/s41541-023-00715-w.
   PubMed Web of Science ®Google Scholar
• Clarke C, Bakaletz LO, Ruiz-Guinazu J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines. 2017;16(7):1–14. doi:10.1080/14760584.2017.1333905.
   PubMed Web of Science ®Google Scholar
• Akkoyunlu M, Melhus A, Capiau C, van Opstal O, Forsgren A. The acylated form of protein D of Haemophilus influenzae is more immunogenic than the nonacylated form and elicits an adjuvant effect when it is used as a carrier conjugated to polyribosyl ribitol phosphate. Infect Immun. 1997;65(12):5010–6. doi:10.1128/iai.65.12.5010-5016.1997.
   PubMed Web of Science ®Google Scholar
• Akkoyunlu M, Ruan M, Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect Immun. 1991;59(4):1231–8. doi:10.1128/iai.59.4.1231-1238.1991.
   PubMed Web of Science ®Google Scholar
• Chichili GR, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, Malinoski F, Sebastian S, Siber G, Malley R, et al. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine. 2022;40(31):4190–8. doi:10.1016/j.vaccine.2022.05.079.
   PubMed Web of Science ®Google Scholar
• Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132–48. doi:10.1016/j.immuni.2019.04.011.
   PubMed Web of Science ®Google Scholar
• Sterrett S, Peng BJ, Burton RL, LaFon DC, Westfall AO, Singh S, Pride M, Anderson AS, Ippolito GC, Schroeder HW, et al. Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. Vaccine. 2020;38(7):1778–86. doi:10.1016/j.vaccine.2019.12.023.
   PubMed Web of Science ®Google Scholar
• Yang J, Sakai J, Siddiqui S, Lee RC, Ireland DDC, Verthelyi D, Akkoyunlu, M. IL-6 impairs vaccine responses in neonatal mice. Front Immunol. 2018;9:3049. doi:10.3389/fimmu.2018.03049.
   PubMed Web of Science ®Google Scholar
• Papillion A, Powell MD, Chisolm DA, Bachus H, Fuller MJ, Weinmann AS, Villarino A, O’Shea JJ, León B, Oestreich KJ, et al. Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-TFH cells. Sci Immunol. 2019;4(39). doi:10.1126/sciimmunol.aaw7636.
   PubMed Web of Science ®Google Scholar
• Kollmann TR, Marchant A, Way SS. Vaccination strategies to enhance immunity in neonates. Science. 2020;368(6491):612–5. doi:10.1126/science.aaz9447.
   PubMed Web of Science ®Google Scholar
• Mastelic B, Kamath AT, Fontannaz P, Tougne C, Rochat AF, Belnoue E, Combescure C, Auderset F, Lambert P-H, Tacchini-Cottier F, et al. Environmental and T cell–intrinsic factors limit the expansion of neonatal follicular T helper cells but May Be circumvented by specific adjuvants. J Immunol. 2012;189(12):5764–72. doi:10.4049/jimmunol.1201143.
   PubMed Web of Science ®Google Scholar
• Clemens EA, Alexander-Miller MA. Understanding antibody responses in early life: baby steps towards developing an effective influenza vaccine. Viruses. 2021;13(7):1392. doi:10.3390/v13071392.
   PubMed Web of Science ®Google Scholar
• Parvathaneni S, Yang J, Lotspeich-Cole L, Sakai J, Lee RC, Akkoyunlu M. IL6 suppresses vaccine responses in neonates by enhancing IL2 activity on T follicular helper cells. NPJ Vaccines. 2023;8(1):173. doi:10.1038/s41541-023-00764-1.
   PubMedGoogle Scholar
• Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, Briso EM, Charland C, Leonard WJ, Ciliberto G, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009;206(1):69–78. doi:10.1084/jem.20081571.
   PubMed Web of Science ®Google Scholar
• Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, Sundaraiyer V, Peng Y, Moyer L, Pride MW, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis. 2022;75(3):390–8. doi:10.1093/cid/ciab990.
   PubMed Web of Science ®Google Scholar
• Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang C-J, Dagan R, Tamms GM, Sterling T, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022;40(1):162–72. doi:10.1016/j.vaccine.2021.08.049.
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. doi:10.1542/peds.2009-3027.
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513–23. doi:10.1016/j.vaccine.2010.06.026.
   PubMed Web of Science ®Google Scholar
• Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun. 1998;66(5):2093–8. doi:10.1128/IAI.66.5.2093-2098.1998.
   PubMed Web of Science ®Google Scholar
• Greenberg JS, Kim HW, Greenley JR. Factors associated with subjective burden in siblings of adults with severe mental illness. Am J Orthopsychiatry. 1997;67(2):231–41. doi:10.1037/h0080226.
   PubMed Web of Science ®Google Scholar